Mankind Pharma's shares fell 2% to Rs 1,985.50, despite the company announcing a 10% YoY rise in net profit to Rs 543 crore for the first quarter of FY25. Revenues increased 12% YoY to Rs 2,893 crore. Brokerages had mixed reactions, with Macquarie, Motilal Oswal, and Kotak Equities offering varied recommendations.
